Drug Information Related to Laronidase
Back
01. TheraCom, an AdvancePCS Company, Awarded Contract to Support Two New ....
Business Editors/Health/Medical Writers BETHESDA, Md.--(BUSINESS WIRE)--May 6, 2003 TheraCom Inc., a specialty pharmacy subsidiary of AdvancePCS (Nasdaq: ADVP), the nation's leading health improvement company, today announced it has been selected by the Genzyme Gen...
02. BioMarin to Host Second Quarter 2008 Financial Results Conference Call...
NOVATO, Calif., July 15 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will host a conference call and webcast on Tuesday, August 5, at 5:00 p.m. ET (23:00...
03. Phase 3 Trial/Study Of Aldurazyme For Mps I Promising | Worldwide ......
Glyko Biomedical Ltd.'s 21%-owned affiliate, BioMarin Pharmaceutical Inc. and Genzyme General have announced detailed results from the six-month double-blind Phase 3 clinical trial of Aldurazyme(TM) (laronidase) and preliminary six-month findings from the trial's ongo...
04. Glyko Biomedical Ltd.'s 21%-owned Affiliate, BioMarin, and Genzyme ......
Business/Health Editors
...
05. First treatment for rare enzyme disorder | FDA Consumer | Find Article...
The first treatment for people with certain forms of a rare genetic disease called MPS I has been approved by the FDA. MPS I occurs when a particular enzyme is absent or malfunctions in the body. The enzyme normally breaks down molecules called glycosaminoglycans (GAG...
06. First treatment for rare enzyme disorder - Updates - Brief Article ......
The first treatment for people with certain forms of a rare genetic disease called MPS I has been approved by the FDA. MPS I occurs when a particular enzyme is absent or malfunctions in the body. The enzyme normally breaks down molecules called glycosaminoglycans (GAG...
07. BioMarin Initiates Phase 1 Clinical Study of PEG-PAL in PKU | PR ......
NOVATO, Calif., May 20 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced that the first patient has initiated treatment in the Phase 1 clinical study of PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase) for the tr...
08. Regulators Okay New Biotech Drug Purification Process from Pall ......
Business Editors/Health/Medical Writers EAST HILLS, N.Y.--(BUSINESS WIRE)--March 10, 2004 Pall PALL - Peace and Long LifePALL - Pressure Alarm Low Low (industrial control description) Corporation (NYSE: PLL) announced today that with collaborators from BioMari...
09. Rodman & Renshaw 3rd Annual Global Healthcare Conference 2006 Pres...
MONTE CARLO, Monaco -- Rodman & Renshaw 3rd Annual Global
Healthcare Conference 2006 takes place May 15-16 in Monte Carlo.For in-depth information about the event visit
http://www.rodmanandrenshaw.com/Conferences.asp?CID=conf9.Below are profiles from Rodman &...
10. Rodman & Renshaw Healthcare Conference 2006 Presenter Profiles. - ...
NEW YORK -- Rodman & Renshaw Healthcare Conference 2006 takes place 6-8 November at the New York Palace Hotel in New York. For in-depth information about the conference, visit http://www.rodmanandrenshaw.com/us06conference. Below are profiles from Rodman & R...
11. Companies Rely on RCT Protein Expression Technology to Make Therapeuti...
TUCSON, Ariz. -- A genetically active DNA sequence that enables high levels of protein expression in mammalian cells is in use worldwide for making products ranging from reagents to therapeutics. The bovine growth hormone bovine growth hormonen. A naturally occurrin...
12. PHASE 3 TRIAL/STUDY OF ALDURAZYME FOR MPS I PROMISING. - Free Online ....
Glyko Biomedical Ltd.'s 21%-owned affiliate, BioMarin Pharmaceutical Inc. and Genzyme General have announced detailed results from the six-month double-blind Phase 3 clinical trial of Aldurazyme(TM) (laronidase) and preliminary six-month findings from the trial's ong...
